ArticleJournal of translational medicine2025
Preliminary evaluation of oxyntomodulin as a biomarker for metabolic risk stratification in adults with obesity.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical obesity in Asian people: bridging the gap between adiposity and disease.Nature reviews. Endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOxyntomodulin (OXM), secreted by enteroendocrine L-cells, regulates energy and glucose homeostasis and is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors (GCGRs), with anorexigenic, insulinotropic, and energy expenditure-enhancing effects. While synthetic analogues of OXM are under investigation as potential anti-obesity therapies, the physiological role and clinical significance of endogenous OXM in human obesity remain incompletely elucidated. This study aimed to evaluate fasting OXM levels and assess their association with anthropometric and biochemical parameters in individuals with varying degrees of excess weight.
methodsThe cross-sectional study included overweight (O1, n = 88) and obese (O2, n = 134) individuals, as well as a healthy control group (CG, n = 39). Body composition was assessed using dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA). Biochemical and hormonal analyses encompassed glucose-insulin homeostasis and lipid profile, with a focus on fasting OXM concentration. Insulin resistance (IR) and β-cell function were evaluated using validated indices.
resultsFasting OXM levels were significantly elevated in the O2 compared to both the O1 and CG (p < 0.0001). OXM positively correlated with several anthropometric parameters, including visceral adipose tissue (VAT) mass and volume in O2. Logistic regression showed that higher OXM was significantly associated with the risk of obesity. Additionally, an increase in the risk of IR and related metabolic complications was observed with an increase in OXM levels, mainly in advanced stages of weight gain.
conclusionsThese findings provide preliminary evidence that OXM constitutes a potential biomarker of visceral adiposity and early metabolic dysregulation, serving as a measurable indicator of IR in obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.